deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT02867592

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

Sponsor: National Cancer Institute (NCI)

Conditions Adrenal Cortical Carcinoma Alveolar Soft Part Sarcoma Central Nervous System Neoplasm Childhood Clear Cell Sarcoma of Soft Tissue Clear Cell Sarcoma of Soft Tissue Ewing Sarcoma Hepatoblastoma Hepatocellular Carcinoma Osteosarcoma Recurrent Adrenal Cortical Carcinoma Recurrent Alveolar Soft Part Sarcoma Recurrent Clear Cell Sarcoma of Soft Tissue Recurrent Ewing Sarcoma Recurrent Hepatoblastoma Recurrent Hepatocellular Carcinoma Recurrent Kidney Wilms Tumor Recurrent Malignant Solid Neoplasm Recurrent Osteosarcoma Recurrent Primary Malignant Central Nervous System Neoplasm Recurrent Renal Cell Carcinoma Recurrent Rhabdomyosarcoma Recurrent Soft Tissue Sarcoma Recurrent Thyroid Gland Medullary Carcinoma Refractory Adrenal Cortical Carcinoma Refractory Alveolar Soft Part Sarcoma Refractory Clear Cell Sarcoma of Soft Tissue Refractory Ewing Sarcoma Refractory Hepatoblastoma Refractory Hepatocellular Carcinoma Refractory Malignant Solid Neoplasm Refractory Osteosarcoma Refractory Primary Central Nervous System Neoplasm Refractory Primary Malignant Central Nervous System Neoplasm Refractory Renal Cell Carcinoma Refractory Rhabdomyosarcoma Refractory Soft Tissue Sarcoma Refractory Thyroid Gland Medullary Carcinoma Refractory Wilms Tumor Renal Cell Carcinoma Rhabdomyosarcoma Soft Tissue Sarcoma Solid Neoplasm Thyroid Gland Medullary Carcinoma Wilms Tumor
Interventions Cabozantinib Cabozantinib S-malate Pharmacological Study
Updated 67 times since 2017 Last updated: Mar 12, 2026 Started: May 18, 2017 Primary completion: Jun 30, 2021 Completion: Jun 27, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Adrenal Cortical Carcinoma and Alveolar Soft Part Sarcoma and is currently ongoing. National Cancer Institute (NCI) leads this study, which shows 67 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jul 2017 · 2 months · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Feb 2022 · 4 months · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Dec 2022 · 6 months · monthly snapshot~Dec 2022 – ~May 2024 · 17 months · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Jan 2025 · 2 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Aug 2025 · 6 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Jan 2026 · 3 months · monthly snapshot~Jan 2026 – ~Mar 2026 · 59 days · monthly snapshot~Mar 2026 – present · 4 months · monthly snapshot

Change History

67 versions recorded

  1. Mar 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2026 — Mar 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Oct 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

▶ Show 62 earlier versions

  1. Feb 2025 — Aug 2025 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2025 — Feb 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Nov 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Oct 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE2

  6. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  7. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE2

  8. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  9. May 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

  10. Dec 2022 — May 2024 [monthly]

    Active Not Recruiting PHASE2

  11. Jun 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE2

  12. May 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  13. Feb 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  14. Oct 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

  15. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

  16. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  17. Apr 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE2

  18. Feb 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE2

  19. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  20. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  21. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  22. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  23. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  24. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  25. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

  26. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  27. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE2

  28. Feb 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  29. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE2

  30. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  31. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  32. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  33. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  34. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  35. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  36. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  37. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  38. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE2

  39. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE2

  40. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE2

  41. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE2

  42. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE2

  43. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  44. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  45. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  46. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  47. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  48. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  49. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  50. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE2

  51. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE2

  52. Jan 2018 — Feb 2018 [monthly]

    Recruiting PHASE2

  53. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

  54. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  55. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE2

  56. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  57. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

  58. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  59. May 2017 — Jul 2017 [monthly]

    Not Yet Recruiting PHASE2

  60. Apr 2017 — May 2017 [monthly]

    Not Yet Recruiting PHASE2

  61. Feb 2017 — Apr 2017 [monthly]

    Not Yet Recruiting PHASE2

  62. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Anchorage, United States , Ann Arbor, United States , Atlanta, United States , Aurora, United States , Baltimore, United States , Bangor, United States , Bellflower, United States , Bethesda, United States , Birmingham, United States and 95 more locations